Dyskinesia Pipeline Insight and Clinical Trial Phases Report | 40+ companies and 45+ Drugs | DelveInsight

DelveInsight's, "Dyskinesia Pipeline Insight, 2023," report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in Dyskinesia pipeline landscape. It covers the Dyskinesia pipeline drug profiles, including Dyskinesia clinical trial and nonclinical stage products. It also covers the Dyskinesia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Dyskinesia Pipeline Report
• DelveInsight's Dyskinesia Pipeline analysis depicts a robust space with 40+ active players working to develop 45+ Dyskinesia pipeline treatment therapies.
• The leading Dyskinesia Companies are working to develop drug candidates to improve the Dyskinesia treatment landscape include Contera Pharma, VistaGen Therapeutics, Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, Teva Pharmaceutical, Luye Pharma Group, IMAC holdings, Neurocrine Biosciences, PolyCore Therapeutics, SOM Biotech, PharmaTher Inc., Appello Pharmaceutical, Sumitomo Pharma, Trevi Therapeutics, Sinopia Bioscience, SAGE Therapeutics, Adhera Therapeutics, and several others.
• Promising Dyskinesia Pipeline Therapies in various stages of developments include JM-010, CP-011, CPL 500036, NLX-112, Dipraglurant, IRL-790, ML-007, Mesocarb, Ketamine, Deutetrabenazine, LPM-3770164, PCT-3012, AQW051, DSP-9632P, AV-101,T 111, SB-0107, SOM3366, and others.
• The Dyskinesia Companies and academics are working to assess challenges and seek opportunities that could influence Dyskinesia R&D. The Dyskinesia pipeline therapies under development are focused on novel approaches to treat/improve Dyskinesia.

Discover more about the latest breakthroughs of the Dyskinesia treatment landscape and Dyskinesia Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dyskinesia Overview

Dyskinesia's are involuntary, erratic, writhing movements of the face, arms, legs or trunk. They are often fluid and dance-like, but they may also cause rapid jerking or slow and extended muscle spasms. They are not a symptom of Parkinson's itself. Rather, they are a complication from some Parkinson's medications. They may be caused by systemic, metabolic, endocrinologic, structural, vascular, infectious or inherited degenerative conditions, or be toxin- or drug-induced. Dyskinesia's usually begin after a few years of treatment with levodopa and can often be alleviated by adjusting dopaminergic medications. Younger people with PD are thought to develop earlier motor fluctuations and dyskinesia's in response to levodopa. Dyskinesia's may be mild and non-bothersome, or they can be severe. Most people with Parkinson's prefer to be "on" with some dyskinesia's rather than "off" and unable to move well. However, for some people, dyskinesia's can be severe enough that they interfere with normal functioning. The most common kind of dyskinesias are "peak dose." These occur when the concentration of levodopa in the blood is at its highest - usually one to two hours after the persons takes it.

Recent Developmental Activities in the Dyskinesia Treatment Landscape

• In June 2022, Addex Therapeutics Ltd announced that it had terminated the Phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients.
• In March 2022, Neurocrine Biosciences, Inc. announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval for DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare.
• In November 2021, Neurocrine Biosciences, Inc. announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29-November 1, 2021.
• In April 2022, PolyCore Therapeutics secured seed financing to address motor symptoms and Dyskinesia associated with Parkinson's Disease.

Explore more about the Dyskinesia Clinical Trials, Therapies, and Companies, just click here only @ https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dyskinesia Emerging Drugs

JM-010: Contera Pharma
JM-010 is developed as an innovative approach to accelerate the development of new treatment options for Parkinson's disease patients suffering from dyskinesia.JM-010 acts as a dual molecular switch by which the target efficacies of two existing and safe medications are perfectly fine-tuned to effectively treat the disease. Using a proprietary formulation, JM-010 targets central mechanisms underlying the development of dyskinesia in Parkinson's disease. JM-010 has successfully demonstrated its efficacy and safety in preclinical studies, as well as in Phase I clinical safety and Phase II clinical proof of concept studies. Currently, JM-010 is undergoing Phase II clinical studies in Europe and US.

NLX 112: Neurolixis
NLX-112 (also known as befiradol or F13640) is a novel compound that activates serotonin 5-HT1A receptors. NLX-112 has two main advantages over older compounds: NLX-112 is extremely selective for the 5-HT1A receptor, with over 1000-fold selectivity compared to other types of receptor types, and NLX-112 is a full agonist at 5-HT1A receptors, maximally activating the receptor. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

CPL 500036: Celon Pharma
CPL500-036 is a novel PDE10A inhibitor developed in laboratories of Celon Pharma S.A. It is characterized by high in vitro and in vivo potency, it is highly selective and has good oral bioavailability (F > 70%) and BBB penetration (B/P = 0,4) in rats. Several behavioural studies have confirmed its antipsychotic and precognitive action in rats (MED > 0,03 mg/kg). CPL500-036 is currently investigated in clinical trials. In October 2019 CelonPharma S.A. completed a phase I clinical trial for CPL500-036.Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Medication-Induced dyskinesia.

Dyskinesia Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies for Dyskinesia. The companies which have their Dyskinesia drug candidates in the most advanced stage, i.e. phase II include, Contera Pharma.

Learn more about the Dyskinesia Emerging Therapies and Key Players, visit here @ https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dyskinesia Pipeline Report
• Coverage- Global
• Dyskinesia Companies- Contera Pharma, VistaGen Therapeutics, Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, Teva Pharmaceutical, Luye Pharma Group, IMAC holdings, Neurocrine Biosciences, PolyCore Therapeutics, SOM Biotech, PharmaTher Inc., Novartis Pharmaceuticals, Sumitomo Pharma, Trevi Therapeutics, Sinopia Bioscience, Adhera Therapeutics, SAGE Therapeutics, and others.
• Dyskinesia Pipeline Therapies- JM-010, CP-011, CPL 500036,NLX-112, Dipraglurant, IRL-790, ML-007, Mesocarb, Ketamine, Deutetrabenazine, LPM-3770164, PCT-3012, AQW051, DSP-9632P, AV-101,T 111, SB-0107, SOM3366, and others.
• Dyskinesia Segmentation: Phases, Product Type, Mechanism of Action, Route of Administration, Molecule Type

Table of Content
1. Introduction
2. Dyskinesia Executive Summary
3. Dyskinesia: Overview
4. Dyskinesia Pipeline Therapeutics
5. Dyskinesia Therapeutic Assessment
6. Dyskinesia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. JM-010: Contera Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Dyskinesia Key Companies
21. Dyskinesia Key Products
22. Dyskinesia- Unmet Needs
23. Dyskinesia- Market Drivers and Barriers
24. Dyskinesia- Future Perspectives and Conclusion
25. Dyskinesia Analyst Views
26. Dyskinesia Key Companies
27. Appendix

For further information on the Dyskinesia Ongoing Clinical Trials Analysis Report @ https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.